StreetInsider.com News Articles

Form SCHEDULE 13G Quantum Biopharma Ltd. Filed by: AdvisorShares Trust

Wed, 08 Jul 2026 17:21:00 -0400

si-local-file:///var/storage/secattach/20260708/26748390.html

Form SCHEDULE 13G Quantum Biopharma Ltd. Filed by: AdvisorShares Trust

Wed, 08 Jul 2026 17:21:00 -0400

si-local-file:///var/storage/secattach/20260708/26748390.html

NetworkNewsAudio Announces Audio Press Release (APR) the Advancement of First-in-Class Treatment for Multiple Sclerosis

Fri, 26 Jun 2026 08:30:00 -0400

AUSTIN, Texas, June 26, 2026 (GLOBE NEWSWIRE) -- via IBN – NetworkNewsAudio announces the Audio Press Release (APR) titled “Novel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple Sclerosis,” featuring Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM).

To hear the NetworkNewsAudio version, visit https://ibn.fm/H77V1

To read the original editorial, visit: https://ibn.fm/wILk2

[Multiple sclerosis] carries a heavy economic burden as well. The global MS therapeutics market was valued at approximately $27.4 billion in 2024 and is forecast to reach $38.62 billion by 2030, driven not by cures

NetworkNewsAudio Announces Audio Press Release (APR) the Advancement of First-in-Class Treatment for Multiple Sclerosis

Fri, 26 Jun 2026 08:30:00 -0400

To hear the NetworkNewsAudio version, visit https://ibn.fm/H77V1

To read the original editorial, visit: https://ibn.fm/wILk2

Quantum BioPharma MS drug candidate moves toward phase 2 trials

Thu, 25 Jun 2026 08:32:59 -0400

Quantum BioPharma Ltd. (NASDAQ: QNTM) announced that its multiple sclerosis drug candidate, Lucid-MS, is preparing to enter phase 2 clinical trials, according to a press release from the company.

Lucid-MS is described by the company as a patented new chemical entity that targets the myelin sheath, the protective nerve covering that MS progressively damages. The compound has shown the ability to prevent and reverse myelin degradation in preclinical models, the company stated.

More than 2.9 million people worldwide are living with MS, a disease for which no cure currently exists. Approved treatments can slow the disease's progression but have not been shown

Quantum BioPharma MS drug candidate nears phase 2 trials

Thu, 25 Jun 2026 08:31:52 -0400

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) is preparing to move its multiple sclerosis drug candidate, Lucid-MS, into phase 2 clinical trials, according to a statement from the company.

Lucid-MS is described by the company as a patented new chemical entity that targets the myelin sheath, the protective coating that MS progressively damages. In preclinical models, the compound has been shown to prevent and reverse myelin degradation, which the company identifies as the underlying mechanism of the disease.

More than 2.9 million people worldwide are currently living with MS. No approved cure exists, and current therapies can slow the disease's progression but

Quantum BioPharma Ltd. (NASDAQ: QNTM) Advancing Innovative, First-in-Class, Patented MS Therapy

Thu, 25 Jun 2026 08:30:00 -0400

NEW YORK, June 25, 2026 (GLOBE NEWSWIRE) -- via BioMedWire — Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) today announces its placement in an editorial published by BioMedWire (BMW), one of 75+ brands within the Dynamic Brand Portfolio@IBN (InvestorBrandNetwork), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community.

To view the full publication, “The Quest to Repair What Multiple Sclerosis Takes Away,” please visit: https://ibn.fm/PJ7yw

Multiple

Quantum BioPharma Ltd. (NASDAQ: QNTM) Advancing Innovative, First-in-Class, Patented MS Therapy

Thu, 25 Jun 2026 08:30:00 -0400

To view the full publication, “The Quest to Repair What Multiple Sclerosis Takes Away,” please visit: https://ibn.fm/PJ7yw

Multiple

Quantum BioPharma Ltd. (NASDAQ: QNTM) Advancing Innovative, First-in-Class, Patented MS Therapy

Thu, 25 Jun 2026 08:30:00 -0400

To view the full publication, “The Quest to Repair What Multiple Sclerosis Takes Away,” please visit:

Quantum BioPharma Ltd. (NASDAQ: QNTM) Advancing Innovative, First-in-Class, Patented MS Therapy

Thu, 25 Jun 2026 08:30:00 -0400

To view the full publication, “The Quest to Repair What Multiple Sclerosis Takes Away,” please visit:

Quantum BioPharma Ltd. (NASDAQ: QNTM) Advancing Innovative, First-in-Class, Patented MS Therapy

Thu, 25 Jun 2026 08:30:00 -0400

To view the full publication, “The Quest to Repair What Multiple Sclerosis Takes Away,” please visit:

Quantum BioPharma Ltd. (NASDAQ: QNTM) Advancing Innovative, First-in-Class, Patented MS Therapy

Thu, 25 Jun 2026 08:30:00 -0400

To view the full publication, “The Quest to Repair What Multiple Sclerosis Takes Away,” please visit:

Quantum BioPharma Ltd. (NASDAQ: QNTM) Advancing Innovative, First-in-Class, Patented MS Therapy

Thu, 25 Jun 2026 08:30:00 -0400

To view the full publication, “The Quest to Repair What Multiple Sclerosis Takes Away,” please visit:

Quantum BioPharma Ltd. (NASDAQ: QNTM) Advancing Innovative, First-in-Class, Patented MS Therapy

Thu, 25 Jun 2026 08:30:00 -0400

To view the full publication, “The Quest to Repair What Multiple Sclerosis Takes Away,” please visit:

The Quest to Repair What Multiple Sclerosis Takes Away